XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Cash Equivalents and Marketable Securities
3 Months Ended
Mar. 31, 2023
Cash and Cash Equivalents [Abstract]  
Cash Equivalents and Marketable Securities

3. Cash Equivalents and Marketable Securities

The amortized costs, unrealized gains and losses and fair values of cash equivalents and marketable securities were as follows (in thousands):

 

 

 

March 31, 2023

 

Description

 

Amortized
Cost

 

 

Unrealized
Gains

 

 

Unrealized
Losses

 

 

Fair
Value

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

24,674

 

 

$

 

 

$

 

 

$

24,674

 

Commercial paper

 

 

2,391

 

 

 

 

 

 

 

 

 

2,391

 

Corporate debt securities

 

 

2,822

 

 

 

 

 

 

 

 

 

2,822

 

U.S. government treasuries

 

 

3,987

 

 

 

 

 

 

 

 

 

3,987

 

Total cash equivalents

 

 

33,874

 

 

 

 

 

 

 

 

 

33,874

 

Short-term marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government treasuries

 

 

22,139

 

 

 

3

 

 

 

(20

)

 

 

22,122

 

Asset backed securities

 

 

484

 

 

 

 

 

 

 

 

 

484

 

U.S. government debt securities

 

 

26,967

 

 

 

19

 

 

 

(6

)

 

 

26,980

 

Certificates of deposit

 

 

948

 

 

 

 

 

 

 

 

 

948

 

Commercial paper

 

 

28,759

 

 

 

6

 

 

 

(5

)

 

 

28,760

 

Corporate debt securities

 

 

19,435

 

 

 

 

 

 

(49

)

 

 

19,386

 

Total short-term marketable securities

 

 

98,732

 

 

 

28

 

 

 

(80

)

 

 

98,680

 

Total

 

$

132,606

 

 

$

28

 

 

$

(80

)

 

$

132,554

 

 

 

 

December 31, 2022

 

Description

 

Amortized
Cost

 

 

Unrealized
Gains

 

 

Unrealized
Losses

 

 

Fair
Value

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

38,191

 

 

$

 

 

$

 

 

$

38,191

 

Total cash equivalents

 

 

38,191

 

 

 

 

 

 

 

 

 

38,191

 

Short-term marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

Certificates of deposit

 

 

948

 

 

 

1

 

 

 

 

 

 

949

 

Commercial paper

 

 

33,318

 

 

 

23

 

 

 

(13

)

 

 

33,328

 

Corporate debt securities

 

 

21,887

 

 

 

6

 

 

 

(40

)

 

 

21,853

 

U.S. government treasuries

 

 

35,608

 

 

 

3

 

 

 

(71

)

 

 

35,540

 

U.S. government debt securities

 

 

24,703

 

 

 

22

 

 

 

(6

)

 

 

24,719

 

Total short-term marketable securities

 

 

116,464

 

 

 

55

 

 

 

(130

)

 

 

116,389

 

Long-term marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

933

 

 

 

 

 

 

(1

)

 

 

932

 

U.S. government treasuries

 

 

3,103

 

 

 

 

 

 

(4

)

 

 

3,099

 

Total long-term marketable securities

 

 

4,036

 

 

 

 

 

 

(5

)

 

 

4,031

 

Total

 

$

158,691

 

 

$

55

 

 

$

(135

)

 

$

158,611

 

All marketable securities held as of March 31, 2023 had contractual maturities of less than one year. There have been no material realized gains or losses on marketable securities for the periods presented. As of March 31, 2023, the Company did not hold any individual securities in an unrealized loss position for 12 months or greater. The Company has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us. The Company considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not significantly impacted. Thus, there has been no change in estimate of expected credit loss during the three months ended March 31, 2023 and no allowance for credit loss was recorded at March 31, 2023 and December 31, 2022. The Company will continue to assess the current and expected future economic and market conditions as further development arises.

See Note 4 for further information regarding the fair value of the Company’s financial instruments.